[
  {
    "ts": null,
    "headline": "Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results",
    "summary": "AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV stock with a Strong Buy rating.",
    "url": "https://finnhub.io/api/news?id=84162b30566b031fd2f5778e89372d55a47095c8c4be23c7927690a903b8a620",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745797235,
      "headline": "Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results",
      "id": 134110498,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193052383/image_1193052383.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV stock with a Strong Buy rating.",
      "url": "https://finnhub.io/api/news?id=84162b30566b031fd2f5778e89372d55a47095c8c4be23c7927690a903b8a620"
    }
  }
]